ORIGINAL ARTICLE

Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome

Robert A Quinn^{1,2}, Vanessa V Phelan², Katrine L Whiteson³, Neha Garg², Barbara A Bailey⁴, Yan Wei Lim¹, Douglas J Conrad⁵, Pieter C Dorrestein² and Forest L Rohwer¹¹Department of Biology, San Diego State University, San Diego, CA, USA; ²Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, CA, USA; ³Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USA; ⁴Department of Mathematics and Statistics, San Diego State University, San Diego, CA, USA and ⁵Department of Medicine, University of California at San Diego, La Jolla, CA, USA

Cystic fibrosis (CF) lungs are filled with thick mucus that obstructs airways and facilitates chronic infections. *Pseudomonas aeruginosa* is a significant pathogen of this disease that produces a variety of toxic small molecules. We used molecular networking-based metabolomics to investigate the chemistry of CF sputa and assess how the microbial molecules detected reflect the microbiome and clinical culture history of the patients. Metabolites detected included xenobiotics, *P. aeruginosa* specialized metabolites and host sphingolipids. The clinical culture and microbiome profiles did not correspond to the detection of *P. aeruginosa* metabolites in the same samples. The *P. aeruginosa* molecules that were detected in sputum did not match those from laboratory cultures. The pseudomonas quinolone signal (PQS) was readily detectable from cultured strains, but absent from sputum, even when its precursor molecules were present. The lack of PQS production *in vivo* is potentially due to the chemical nature of the CF lung environment, indicating that culture-based studies of this pathogen may not explain its behavior in the lung. The most differentially abundant molecules between CF and non-CF sputum were sphingolipids, including sphingomyelins, ceramides and lactosylceramide. As these highly abundant molecules contain the inflammatory mediator ceramide, they may have a significant role in CF hyperinflammation. This study demonstrates that the chemical makeup of CF sputum is a complex milieu of microbial, host and xenobiotic molecules. Detection of a bacterium by clinical culturing and 16S rRNA gene profiling do not necessarily reflect the active production of metabolites from that bacterium in a sputum sample.

The ISME Journal (2016) 10, 1483–1498; doi:10.1038/ismej.2015.207; published online 1 December 2015

Introduction

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations within the CF transmembrane conductance regulator (CFTR). CFTR mutations result in abnormal ion transport across the epithelium leading to the production of thick bronchial mucus (Knowles *et al.*, 1983; Quinton, 1983, 2008; Widdicombe *et al.*, 1985). This mucus provides niche space for microbial colonization, resulting in chronic lung infections that begin in infancy and persist throughout a patient's lifetime. The CF lung is a polymicrobial infection containing viruses (Willner *et al.*, 2009, 2012), fungi (Delhaes *et al.*, 2012; Willger *et al.*, 2014) and bacteria (Rogers *et al.*, 2003; Guss *et al.*, 2011; Blainey *et al.*, 2012;

Filkins *et al.*, 2012; Goddard *et al.*, 2012; Lim *et al.*, 2013, 2014; Maughan *et al.*, 2012; Zhao *et al.*, 2012; Price *et al.*, 2013; Salipante *et al.*, 2013; Zemanick *et al.*, 2013; Cuthbertson *et al.*, 2014; Smith *et al.*, 2014) (literature summarized in Supplementary Table S1) co-existing in a complex community. The community is diverse during youth, but as patients age, this diversity decreases and specific pathogens take over (Harrison, 2007; Zhao *et al.*, 2012).

Pseudomonas aeruginosa is traditionally regarded as the principle pathogen of CF disease and is one of the most common bacteria cultured from CF patients (Harrison, 2007). This bacterium is known to produce a myriad of small molecules that damage both host and microbial cells (Allen *et al.*, 2005; Irie *et al.*, 2005; Zulianello *et al.*, 2006; Rada *et al.*, 2008; Heeb *et al.*, 2011). Rhamnolipids (Zulianello *et al.*, 2006), phenazines (Allen *et al.*, 2005) and quinolones (Calfee *et al.*, 2001) have been shown to be important for the pathogenesis of this bacterium *in vitro*, but their role in CF disease is less well known. These molecules have been detected in CF

Correspondence: RA Quinn, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92037, USA.
E-mail: quinnr1234@gmail.com

Received 19 May 2015; revised 19 October 2015; accepted 12 October 2015; published online 1 December 2015

sputum (Kownatzki *et al.*, 1987; Collier *et al.*, 2002) and the redox active phenazines have been shown to accumulate as lung function declines (Hunter *et al.*, 2012), but beyond these studies little is known about the diversity of these molecules in the lung, how their chemistry differs between the lung environment and the laboratory and how detection of *P. aeruginosa* metabolites is reflected in other diagnostic methods on the same sample. A better understanding of the chemistry of these molecules in the lung environment is required to realize their importance in the pathology of CF disease.

Irrespective of *P. aeruginosa* metabolites, there is limited information on the overall molecular constituents of CF lung secretions. Metabolomics studies have investigated the microbial and host molecules in sputum (Jones *et al.*, 2000; Palmer *et al.*, 2007; Bensen *et al.*, 2011; Yang *et al.*, 2012; Twomey *et al.*, 2013), breath gas or breath condensate (Barker *et al.*, 2006; Celio *et al.*, 2006; Newport *et al.*, 2009; Robroeks *et al.*, 2010; Montuschi *et al.*, 2012; Monge *et al.*, 2013) and bronchiolar lavage fluid (Wolak *et al.*, 2009; Eiserich *et al.*, 2012; Yang *et al.*, 2012). These studies demonstrated that core primary metabolites including ethanol, acetate and 2-propanol distinguished CF from non-CF samples (Montuschi *et al.*, 2012) and that the fermentation product 2,3-butanedione was associated with microbial activity (Whiteson *et al.*, 2014). A study investigating host-derived lipid mediators showed a complex network of inflammatory lipid signaling in CF lungs (Yang *et al.*, 2012). These metabolomics studies have identified important molecules in CF disease that are potential markers of host or microbial physiological states (Collier *et al.*, 2002; Price-Whelan *et al.*, 2006; Diggle *et al.*, 2007; Mitchell *et al.*, 2010; Pierson and Pierson, 2010). However, the chemistry of CF lung secretions remains poorly characterized, particularly concerning specialized metabolites that function outside primary metabolism.

There are major challenges when studying the CF metabolome and determining the role of particular molecules *in vivo*. Principally, the chemical milieu is extremely complex, containing thousands of host and microbial metabolites (Molloy, 2014). Comprehensive and untargeted assessments of the CF airway metabolome are hard to interpret, because annotation of detected molecules is still a laborious process and metabolomics databases are not easily searchable (Dettmer *et al.*, 2007). Molecular networking (Bandeira *et al.*, 2007; Watrous *et al.*, 2012), which compares the fragmentation patterns of individual molecules to show structural relationships, alleviates some of these challenges. This tool enables the investigation of structural relatedness within a metabolome and can be used as a dereplication strategy or for data visualization to investigate small molecule chemistry (Moree *et al.*, 2012; Watrous *et al.*, 2012; Nguyen *et al.*, 2013; Sidebottom *et al.*, 2013; Yang *et al.*, 2013). Molecular networking has

been used to study the specialized metabolome of *P. aeruginosa*, where it revealed chemical details of the antibiotics and quorum-sensing molecules it produces (Moree *et al.*, 2012; Watrous *et al.*, 2012; Nguyen *et al.*, 2013).

In this study, a combination of 16S rRNA gene sequencing and metabolomics was used to analyze sputa from CF patients and non-CF volunteers. A molecular networking approach was used because of its ability to comprehensively assess the chemistry of microbial, host and xenobiotic metabolites in an untargeted manner. Although known microbial metabolites were rare in CF sputum, sphingolipids were highly abundant. *P. aeruginosa* specialized metabolites, including phenazines, rhamnolipids and quinolones, were detected, but their prevalence did not correspond to 16S rRNA gene sequence profiles or clinical cultures. Furthermore, the metabolites produced by *P. aeruginosa* in the lung were different from that produced in laboratory cultures. The abundant sphingolipids, particularly sphingomyelin, may be clinically relevant, as this molecule contains the inflammatory lipid ceramide, creating a reservoir of hyperinflammatory responses that may be damaging to the lungs.

Materials and methods

Additional methodological details for each section are available in the Supplementary information.

Sample collection

Seven CF samples and two non-CF samples were collected in October 2012 at the Adult CF Clinic at the University of California, San Diego Medical Center, and four non-CF samples were collected from volunteers at San Diego State University. These samples were brought to a 12-ml total volume in phosphate-buffered saline if the sample was less than 12 ml. An additional 27 sputa were collected during a 6-month period in 2013–2014 at the UCSD adult CF clinic during routine clinical visits, because a smaller sample volume was needed for only targeted MS analysis they were not diluted. All samples were collected with the same clinical sampling procedure. After a mouthwash to minimize oral contamination, samples were expectorated into a sterile sputum cup following hypertonic saline inhalation for 30 min. The initial CF and non-CF sputum samples were frozen on dry ice, whereas the 27 additional sputum samples were stored immediately in liquid nitrogen. All samples were collected in compliance with the University of California Institutional Review Board (HRPP 081500) and San Diego State University Institutional Review Board (SDSU IRB#2121) requirements and written consent was obtained.

Bacterial culturing and metabolite extraction

P. aeruginosa cultures were spot plated onto a single ISP2 plate and grown overnight. Extracts were taken by cutting out the agar around the colony and extracting in 200 μ l of ethyl acetate by brief vortexing and incubation for 1 h. The top ethyl acetate layer was removed and dried in a centrifugal evaporator. The remaining sample was extracted in 200 μ l of methanol by vortexing and incubation for 1 h. The methanol extract was then spun in a tabletop centrifuge at 10 000 *g* for 30 s. The methanol extract supernatant was then added to the dried ethyl acetate extract, dried down and frozen at -80°C until mass spectrometry analysis. The same cultures were also grown in artificial sputum medium in thin glass capillary tubes simultaneously overnight according to the method developed in Quinn *et al.* (2014), which is meant to mimic the conditions of a CF bronchiole. Metabolites were extracted with the same solvent procedure, but for these samples the liquid media was removed from the capillary tube first with a syringe and then added to the ethyl acetate solvent.

Microbiome sequence profiling

The microbiome sequencing was performed according to Quinn *et al.* (2014) where the same CF sputum profiles are also published. Briefly, DNA was extracted from 100 μ l of sputum obtained from a -80°C aliquot immediately after thawing by directly pipetting the sample into 200 μ l of the Trizol reagent (Life Technologies, Carlsbad, CA, USA). Extraction of DNA was done using the manufacturers protocol for DNA extraction. Total DNA was sent to the Genomics Core at Michigan State University for 16S rRNA gene sequencing. The V4 region (515F/806R) of the bacterial 16S rRNA gene was amplified by PCR (Caporaso *et al.*, 2011). A standard Illumina MiSeq v2 reagent kit (San Diego, CA, USA) was used to prepare for paired end, 2×250 bp sequencing on the Illumina MiSeq format. Data processing, quality control and operational taxonomic unit clustering in mothur (Schloss *et al.*, 2009) are described in Supplementary methods. Briefly, the Silva database (Quast *et al.*, 2013) was used with Ribosomal Database Project taxonomy (Cole *et al.*, 2005) to identify the taxonomy of operational taxonomic units at a cluster cutoff of 97%. Sequence profiles were rarefied to a minimum of 4000 sequence reads per sample, using the *rrarefy* command in the 'vegan' package in the R statistical software (Oksanen *et al.*, 2015).

Sputum metabolite extractions and LC-MS/MS

All sputum samples were defrosted and 20 μ l was extracted in 100 μ l of LC-MS/MS grade ethyl acetate by brief vortexing and incubation for 1 h. The top ethyl acetate extracted layer was then removed and dried in a centrifugal evaporator. The remaining sample was then mixed with 100 μ l of LC-MS/MS

grade methanol by vortexing and incubation for 1 h, and centrifugation in a tabletop centrifuge at 10 000 *g* for 30 s. The methanol extract supernatant was then added to the dried ethyl acetate extract, dried down and frozen at -80°C until tandem mass spectrometry (MS/MS) analysis. Liquid chromatography was performed with ThermoScientific UltraMate 3000 Dionex (Sunnyvale, CA, USA). Mass spectrometry was performed using a Bruker Daltonics Maxis qTOF mass spectrometer (Billerica, MA, USA) equipped with a standard electrospray ionization source. The mass spectrometer was tuned by infusion of Tuning Mix ES-TOF (Agilent Technologies, Santa Clara, CA, USA) at a 3 μ l min^{-1} flow rate. For accurate mass measurements, lock mass internal calibration used a wick saturated with hexakis (1H,1H,3H-tetrafluoropropoxy) phosphazene ions (Synquest Laboratories, Alachua, FL, USA, *m/z* 922.0098) located within the source. High-performance liquid chromatography (HPLC)-MS/MS analysis was performed using Phenomenex (Torrance, CA, USA) Luna 5 μ m C18(2) HPLC column (2.0 mm $\times$ 250 mm) on the initial seven CF samples and on the additional 27 samples for targeted analysis. A Phenomenex Kinetex 2.6 μ m C18 (30 $\times$ 2.10 mm) ultra performance liquid chromatography (UPLC) column was used to obtain metabolomics data from the seven CF samples and six non-CF samples for statistical comparison of molecule abundances. Both analyses utilized a 20- μ l injection volume. A linear water-acetonitrile gradient (from 98:2 to 2:98 water:acetonitrile) containing 0.1% formic acid was utilized (HPLC: 54 min gradient; UPLC: 14 min gradient). The flow rate was 0.2 ml min^{-1} for the HPLC analysis and 0.5 ml min^{-1} for the UPLC analysis. The mass spectrometer was operated in data-dependent positive ion mode, automatically switching between full-scan MS and MS/MS acquisitions for both the UPLC and HPLC analysis. Full-scan MS spectra (*m/z* 50–2000) were acquired in the TOF and the top 10 most intense ions in a particular scan were fragmented using collision induced dissociation at 35 eV for +1 ion and 25 eV for +2 ions in the collision cell.

Statistical analysis

Abundances of molecules were calculated using the MS_1 -based area under the curve and normalized for the original sample volume. Putative assignments of the source or annotation of a molecular feature were based on MS/MS data and analyzed with molecular networking. For random forests analysis, each area under the curve abundance in the UPLC metabolomes was normalized to the total abundance of all molecules detected to generate an abundance matrix. This matrix was imported to the R-Studio software package v0.97.318 (Boston, MA, USA) for statistical analysis. Shannon–Weiner indices were calculated based on the normalized abundance of each molecular feature or each bacterial genus using

the 'vegan' package in R (Oksanen *et al.*, 2015). A correlation between these two indices was then tested using Pearson's *r* and statistical differences tested with the Student's *t*-test. A supervised random forests (5000 trees) was done on the abundance matrix using the R 'randomForest' package v4.6-7 (Boston, MA, USA). A variable importance plot (VIP) of the random forests was used to detect molecules enriched in CF compared with non-CF samples. Statistical significance between CF and non-CF metabolite abundances was then verified with the Wilcoxon rank-sum test after normalization for original sample volume.

Molecular networking

All LC-MS/MS data collected were converted into the .mzXML format using Bruker DataAnalysis software v4.1 (Billerica, MA, USA). Molecular networking was carried out as described in Bandeira *et al.* (2007), Watrous *et al.* (2012) and Yang *et al.* (2013) using our in-house bioinformatics workflow (gnps.ucsd.edu). To detect *P. aeruginosa* metabolites, pure cultures of CF and non-CF isolates were grown on ISP2 media, and the media and colonies were extracted with the same solvents as the sputum samples and run with the same LC-MS/MS methods. Highlighting individual nodes by their source in Cystoscape (San Diego, CA, USA) allowed for assessment of the putative source of the metabolites detected. The pure culture data were seeded into the network of the sputa data, and networks were analyzed using the GNPS database and the Cytoscape software (Shannon *et al.*, 2003). *P. aeruginosa* metabolites and sphingomyelin were identified by matching retention time and MS/MS spectra according to the metabolomics standard initiative level 1 annotation guidelines (Sumner *et al.*, 2007), previously unidentified molecular relatives of these metabolites are considered as level 2 and all other microbial metabolites are unknown (level 4 compounds).

Results

Initially, seven CF sputum samples were collected from patients with a varied clinical culture history to compare clinical culture results with metabolomics and 16S rRNA gene sequencing. Six non-CF sputa (obtained from healthy human individuals without CF disease using the same induced sputum method) were used for a statistical comparison to the CF metabolomic data from these original patients. Sputum samples from 27 additional CF patients were then collected and analyzed with targeted metabolomics and clinical culture for a more in-depth investigation of the relationships between metabolomics and *P. aeruginosa* culture results. The molecular abundances in this study were determined using area under the curve of the MS,

signal of each unique ion to provide accurate abundance information on molecules detected. Annotation and assignment of molecular sources were based on molecular networking of MS/MS spectra from sputum with known spectra in the GNPS mass spectrometry database (gnps.ucsd.edu).

Global chemistry of CF sputum

An HPLC-MS/MS approach was used for an initial chemical investigation of the seven CF sputa. Metabolomics data were also generated on bacterial CF isolates that were detected in the microbiomes, including a *P. aeruginosa* strain (PANmFLR01), methicillin-sensitive *Staphylococcus aureus* (SaFLR01), methicillin-resistant *S. aureus* (MRSAFLR01), *Stenotrophomonas maltophilia* (SmFLR01), *Escherichia coli* (EcFLR01) and *Streptococcus salivarius* (SsFLR01). The sputum and microbial metabolomics data were co-networked together with stringent parameters using our in-house molecular networking bioinformatics tool GNPS to identify putative microbial metabolites by matching MS/MS spectra between the samples and with our spectral libraries (Figure 1, Supplementary Figure S1). Molecular networking is based on the property that molecules of similar structure fragment similarly resulting in similar MS/MS spectra. This information is visualized using nodes as a proxy for MS/MS spectra and the thickness of the edges representing the similarity between the nodes. For visualization of the CF sputum molecular network, the nodes are colored based upon the sample origin, and the 'V' shape indicates a match to the GNPS spectral libraries (Figure 1). In the global molecular network, 1352 unique MS/MS spectra were observed. Putatively annotated molecules included host lipids, amino acids, various xenobiotics (particularly drugs given to the patients) and *P. aeruginosa* specialized metabolites (Figure 1). A total of 2.5% of detected molecules could be annotated through GNPS, 3.8% matched to a microbial metabolome, the remaining 96.2% were only detected in CF sputum, and were therefore assigned as host or other microbial molecules (Figure 2a). Only 1.0% of molecules detected in the CF sputa matched a *P. aeruginosa* pure culture. A number of phosphoethanolamines were present in both CF sputum and bacterial cultures, indicating that this molecular family is shared between bacteria and the host (Figure 1).

Microbiome and metabolome diversity

Clinical culture results and 16S rRNA gene amplicons were sequenced to generate microbial profiles of the initial seven CF patients in this study. The microbiome profiles differed between all patients and did not coincide with culturing results (Figure 2b, Table 1). Two of the patient microbiomes

Figure 1 Molecular network of CF sputa and bacterial isolate HPLC-MS/MS metabolomic data generated on GNPS. The network was visualized using the Cytoscape software. Each node represents a unique spectrum that was detected at least twice in the data set and is colored by its sample of origin according to the legend. Nodes that were detected in multiple bacteria as well as a sputum sample are considered together regardless of which bacteria were represented. Bacterial-only nodes are colored gray and were not considered for subsequent sputum statistical analysis and ISP2 media blank nodes are colored black to be ignored as a background. Nodes that hit to the GNPS database based on the molecular networking algorithm (Watrous *et al.*, 2012) are shaped as a 'V' and circular nodes are those that are not known in GNPS. Molecular families and identified molecules are highlighted. *Singleton nodes are those that did not have any molecular relatives and are not shown in the network.

were dominated by *Rothia* spp. and *Streptococcus* spp. (CF10, CF11), two were dominated by *Pseudomonas* spp. (CF9 and CF13) and the other three were unique (CF1, CF6 and CF12, Figure 2b). *Pseudomonas* spp. constituted >5% of the 16S rRNA gene sequence reads in only three of the patients (CF1, CF9 and CF13, Table 1). As the initial patients in this study were selected based on varied culture results, we investigated the literature to assess how often *P. aeruginosa* was the dominant bacterium in microbiome profiles without this selection (Supplementary Table S1). From 18 studies comprising 393 patients, 60% of patients had *P. aeruginosa* as the most relatively abundant bacterium (Supplementary Table S1). This demonstrated that while *P. aeruginosa* is most often the dominant pathogen in adult CF patients, other bacteria are dominant in 40% of individuals. To compare microbiome and metabolome diversity, Shannon–Weiner indices were calculated on the abundance matrices from both data types on the same samples. The CF metabolomes were significantly more diverse than non-CF (Shannon–Weiner index, one-tailed Student's *t*-test; $P=0.00003$, $df=13$), but the 16S rRNA gene profiles produced

the opposite trend ($P=0.0010$) (Supplementary Figure S2). There was no significant Pearson's correlation between microbial diversity and the metabolome diversity in either CF or non-CF populations (Supplementary Table S2, $r=-0.12$, and $r=0.43$, respectively).

P. aeruginosa specialized metabolites in sputa

P. aeruginosa metabolites were detected in four of the seven initial CF patients within the global molecular network (Figure 1, Table 2). The specific chemistry of these metabolites was then analyzed by networking individual patients with *P. aeruginosa* data alone (Figure 3, Table 2, Supplementary Figure S3). Patient CF9 had the largest relative abundance of *P. aeruginosa* in the microbiome (75.0%, Table 1), and quinolones were detected in this patient's metabolome; however, the overall abundance of these molecules was only 0.03% of the total metabolome. The most abundant specialized metabolite in CF9 was 2-heptyl-4-quinolone (HHQ), which made up 0.02% of the total counted ions. For comparison, the most abundant host metabolite in CF9 (sphingomyelin) was 1.1% and

Figure 2 (a) Bar chart of the distribution of the detected molecules based on the network mapping. Molecules are assigned to a particular bacterium when a spectrum was detected in sputum and that bacterium only. Shared molecules between multiple bacteria are also shown. (b) Clinical culture results and 16S rRNA microbiome profiles of the seven sequenced CF sputum samples in this study. Microbiome profiles were generated using 16S rRNA gene amplicon sequencing and operational taxonomic unit clustering using Mothur, 19 of those most abundant are shown here while the rest are clustered into 'other' as they were of very low abundance.

Table 1 Clinical culture history and 16S rRNA gene profile results of CF and non-CF sputa

Sample	Clinical culture results	Dominant bacterium in microbiome	% Most dominant bacterium	% <i>Pseudomonas</i> abundance	# of Sequence reads
CF1	<i>P. aeruginosa</i> , <i>S. maltophilia</i>	<i>Streptococcus</i>	27.5	5.00	57 206
CF6	<i>E. coli</i>	<i>Escherichia</i>	52.52	1.74	17 977
CF9	<i>P. aeruginosa</i>	<i>Pseudomonas</i>	75.00	75.00	50 875
CF10	<i>Achromobacter xylosoxidans</i>	<i>Streptococcus</i>	44.40	0.018	63 917
CF11	<i>P. aeruginosa</i> , <i>S. maltophilia</i>	<i>Streptococcus</i>	34.80	0.11	40 948
CF12	MRSA, <i>P. aeruginosa</i>	<i>Stenotrophomonas</i>	45.67	0.99	39 029
CF13	MRSA	<i>Pseudomonas</i>	67.87	66.41	62 187
H1	NA	<i>Streptococcus</i>	16.48	0.005	54 333
H2	NA	<i>Burkholderia</i>	22.73	0.22	4743
H3	NA	<i>Veillonella</i>	27.95	0.001	56 836
H4	NA	<i>Geobacillus</i>	36.32	0.005	32 899
H5	NA	<i>Streptococcus</i>	15.22	0.002	69 545
H6	NA	<i>Streptococcus</i>	17.02	0.002	54 559

Abbreviations: CF, cystic fibrosis; MRSA, methicillin-resistant *S. aureus*; NA, not applicable.

the most abundant xenobiotic (azithromycin) was 2.1%. This demonstrated that while detectable in sputum, the *P. aeruginosa* specialized metabolites were at a low relative abundance compared with other molecules, even in a patient dominated by this bacterium. A total of six unique quinolones were detected in patient CF9 (Figure 3, Table 2), including the two base quinolones: 2-heptyl-4-hydroxyquinolone-N-oxide (HQNO, m/z 260.19) and

HHQ (m/z 244.17). The remaining six quinolones were structural derivatives of these molecules, differing only in the length and unsaturation of the aliphatic chain (Figure 3). The pseudomonas quinolone signal (PQS, 2-heptyl-3-hydroxy 4-quinolone) was not detected, even though its precursor HHQ was the most abundant quinolone in CF9 (Figure 3). To further investigate the chemistry and prevalence of *P. aeruginosa* metabolites, a targeted analysis

Table 2 Chemical characteristics and abundances of *P. aeruginosa* specialized metabolites detected in CF sputum

Molecular family	Compound name	Form	Calculated <i>m/z</i>	Sample	Retention time (min)	Measured <i>m/z</i>	Peak intensity in sputum	Δ ppm
Phenazine	1-HP	H+	197.0709		25.3	197.07		4.06
				CF6	25.1	197.07	1.1×10^4	3.04
	?-HP	H+	**	CF6	22.4	197.07		
	PYO	H+	211.0866		14.5	211.08	3.8×10^4	0.95
	PYO analog	H+	**	CF6	18.7	211.08		
Quinolone	PCA	H+	225.0659		26.2	225.06		5.78
				CF6	25.9	225.06	5.9×10^4	2.22
	5-MPCA	H+	239.0815	MPA01, CF6	12.7	239.08	7.6×10^4	1.67
	HHQ	H+	244.1696	PAmFLR02	26.3	244.17		4.91
				CF9	26.1	244.16	4.9×10^5	0.41
	HQNO	H+	260.1645	PAmFLR02	26.5	260.16		6.53
				CF9	26.3	260.16	1.5×10^4	-1.92
	db-NHQ	H+	270.1852	AmFLR02	29.5	270.18		2.96
				CF9	29.2	270.18	2.3×10^4	0.74
	NHQ	H+	272.2009	PAmFLR02	29.9	272.20		5.14
				CF9	29.7	272.20	1.6×10^5	1.1
	NQNO	H+	288.1958	PAmFLR02	29.9	288.19		4.16
				CF9	29.8	288.19	1.7×10^4	1.73
Rhamnolipid	db-UHQ	H+	298.2165	PAmFLR02	31.5	298.21		3.69
	Rha-Rha-C10-C10	Na+	673.3770	CF9	31.2	298.21	3.4×10^4	2.35
				PAmFLR02	34.0	673.37		1.63
				CF6	33.9	673.37	6.2×10^3	-1.78
				CF9	33.9	673.37	4.3×10^4	-0.74
				CF10	33.9	673.37	5.9×10^3	-1.78
				CF11	33.9	673.37	6.9×10^4	-2.08

Abbreviations: CF, cystic fibrosis; db-NHQ, 2-nonenyl-4-hydroxyquinolone; db-UHQ, 2-undecenyl-4-hydroxyquinolone; 1-HP, 1-hydroxyphenazine; HHQ, 2-heptyl-4-hydroxyquinolone; HQNO, 2-heptyl-4-hydroxyquinolone-N-oxide; NHQ, 2-nonyl-4-hydroxyquinolone; NQNO, 2-nonyl-4-hydroxyquinolone N-oxide; PCA, phenazine-1-carboxylic acid; PYO, pyocyanin; UHQ, 2-undecyl-4-hydroxyquinolone; 5-MPCA, 5-methylphenazine-1-carboxylic acid; **, same as above. Strain MPA01 is a laboratory strain, PAmFLR01 is a non-mucoid CF isolate and PAmFLR02 is a mucoid isolate. *m/z* = mass-to-charge ratio; Δ ppm = change in parts per million from exact mass.

was performed on the additional 27 CF sputa and compared with clinical culture results. Fourteen of these additional samples were positive by *P. aeruginosa* targeted metabolomics. Six of these samples were positive for *P. aeruginosa* culture, but negative by metabolite detection, and four contained a *P. aeruginosa* metabolite, but were negative by culture results (Table 3). Incorporating the initial seven samples, 50% of the sputa that were negative by *P. aeruginosa* clinical culture ($n=12$) contained at least one specialized metabolite from this bacterium. HHQ was detected in four samples, 2-nonyl-4-quinolone in eleven and both molecules were found in three (Table 3). Similar to CF9, PQS and C9-PQS were not detected in any of these sputum samples even when HHQ was present.

To test whether the chemical nature of the *P. aeruginosa* quinolone production in sputum was specific to growth in the CF lung environment, three different CF strains of *P. aeruginosa* were grown in a CF mucus bronchiole model that mimics lung conditions (WinCF model) (Quinn *et al.*, 2014) and compared with metabolite production when grown on ISP2 aerobic media. The quinolone production in the WinCF model matched that of the sputum, where the isolates produced abundant HHQ, HQNO and NQNO (C9-HQNO), but not PQS or C9-PQS (Supplementary

Figure S4). However, PQS and C9-PQS were produced when *P. aeruginosa* was grown on the aerobic ISP2 media (Supplementary Figure S4).

Phenazines were detected in patient CF6 (Figure 3, Table 2) and in three of the additional twenty-seven samples (Table 3). These known phenazines included 1-hydroxyphenazine (1-HP), phenazine-1-carboxylic acid and a variant of pyocyanin (PYO) (Figure 3, Supplementary Figure S3). Additional putative phenazines were also detected in the raw data including a phenazine with the same exact mass and similar MS/MS fragmentation pattern to 1-HP (*m/z* 197.07), but a different retention time when compared with *P. aeruginosa* pure culture (Supplementary Figure S3). This indicated that this metabolite was likely an analog of 1-HP, probably differing in the position of the hydroxyl group. The PYO variant shared the same mass as PYO, but both the fragmentation pattern and retention time differed (Supplementary Figure S3). The similarity of MS/MS fragmentation between the detected phenazine and PYO suggests that their structures were closely related.

Despite the diversity of rhamnolipids produced by *P. aeruginosa* in culture, only the rhamnolipid Rha-Rha-C10-C10 (*m/z* 673.37 ([M+Na]⁺)) was

Figure 3 Molecular clusters of *P. aeruginosa* quinolones, phenazines and rhamnolipids. The metabolomes of CF9 and CF6 were networked separately with PANmFLR01 to explore the specific chemistry of these molecules in the samples that they were detected in. The rhamnolipid cluster is from the network in Figure 1, because they were detected in multiple samples. Nodes are colored and shaped by their sample origin as indicated in the legend. The name and chemical structure of each detected *P. aeruginosa* metabolite in sputum is shown.

found in CF sputum (Figure 3). This molecule was detected in four of the original CF samples (Figure 3, Supplementary Figure S3, Table 2), two of which were negative by clinical culture (Supplementary Table S3) and three of the additional twenty-seven samples (Table 3). The peak intensity of Rha-Rha-C10-C10 was highest in sputum from patient CF9, who had the highest proportion of *P. aeruginosa* in the microbiome (Table 1). Even though Rha-Rha-C10-C10 was detected, the microbiome of patients CF6, CF10 and CF11 contained less than 2% *P. aeruginosa*.

Xenobiotics in CF sputa

A number of exogenous metabolites were identified in the original seven CF sputa, including anti biotics, antifungals and antidepressants (Figure 1, Supplementary Figure S5). Caffeine was detected in four CF samples (CF1, CF6, CF11 and CF13) and one non-CF sample (H1) (Figure 4). The antibiotic azithromycin was detected in prescribed patients (CF1, CF9 and CF13) and aztreonam (Figure 4) was only detected in CF9; although several other patients were prescribed the medication (Supplementary

Table 3 Extracted ion abundance of *P. aeruginosa* specialized metabolites in the additional 27 sputum samples and their *P. aeruginosa* clinical culture results

	Quinolones				Rhamnolipid	Phenazines		<i>P. aeruginosa</i> culture
	HHQ	NHQ	PQS	C9-PQS	Rha-Rha-C10-C10	PCA	PYO	
CF6	0	0	0	0	0	0	0	+
CF26	0	0	0	0	0	0	1780	–
CF28	0	0	0	0	0	0	0	–
CF29	0	0	0	0	0	0	0	–
CF30	0	0	0	0	15 712	0	0	+
CF31	0	3484	0	0	0	0	0	–
CF33	0	0	0	0	0	0	0	–
CF34	0	0	0	0	0	0	0	–
CF35	0	0	0	0	0	0	0	+
CF36	0	4072	0	0	0	0	0	+
CF37	0	0	0	0	0	0	0	–
CF38	0	4060	0	0	0	0	0	+
CF39	0	150 652	0	0	0	0	0	+
CF40	0	0	0	0	0	0	0	+
CF41	0	0	0	0	0	0	0	+
CF42	0	3620	0	0	0	1992	0	–
CF43	0	0	0	0	0	0	0	–
CF44	1216	4460	0	0	0	0	0	+
CF45	0	116 548	0	0	0	0	0	+
CF46	2396	0	0	0	7760	0	0	+
CF47	0	0	0	0	0	0	0	+
CF48	162 940	511 380	0	0	6988	0	0	+
CF49	0	0	0	0	0	0	0	+
CF50	0	3392	0	0	0	0	0	+
CF51	0	0	0	0	0	2120	0	+
CF52	0	3084	0	0	0	0	0	+
CF53	38 012	267 824	0	0	0	0	0	+

Abbreviations: CF, cystic fibrosis; HHQ, 2-heptyl-4-quinolone; NHQ, 2-nonyl-4-hydroxy-quinolone; PCA, phenazine-1-carboxylic acid; PQS, pseudomonas quinolone signal; PYO, pyocyanin.

Table S3). In addition, the antibiotics sulfamethoxazole and trimethoprim (Figure 4) were detected in several patients (CF1, CF6, CF9 and CF10) even though these drugs were not known to have been administered recently. The antifungal itraconazole was detected in patient CF9 (Figure 4). Anti-depressants citalopram and amitriptyline were detected in CF6 and CF13, respectively (Figure 4). Metabolism and transformations of these xenobiotics were also observed, including loss of a sugar moiety of azithromycin, desulfated aztreonam, acetylated sulfamethoxazole, and demethylation and/or hydroxylation of caffeine, citalopram, amitriptyline and itraconazole (Figure 4). There was a positive correlation between levels of azithromycin in sputum with levels of *P. aeruginosa* reads and the *P. aeruginosa* rhamnolipid Rha-Rha-C10-C10 (one-tailed test of Pearson's $r=0.72$ and $r=0.89$ respectively, $P<0.05$).

Metabolites that distinguish CF from non-CF

After assessment of the overall chemistry and putative source assignments of the molecules detected, an UPLC-MS/MS method was used to generate metabolomic data on the initial seven CF sputa and an additional six non-CF sputa for statistical comparisons between these two groups. A random forest statistical approach was used to

identify which molecules best differentiated the CF from non-CF metabolomes based on their MS_1 abundances. Although this represents a relatively small sample size, our statistical approach reveals molecules that are drastically different in abundance between CF and non-CF lending the findings more broadly applicable. Thirty differential molecular features were identified in the random forests VIP as significantly different between CF and non-CF (Supplementary Table S4, Supplementary Figure S6). The source of these molecules was then determined by matching their parent mass in the molecular network and determining which group they were from xenobiotics, CF only, non-CF only, shared or matching a bacterium. None of the distinguishing molecules were known to be bacterial, their source was CF only (18/30), non-CF only (1/30) or both (11/30, Supplementary Table S4). This indicated that the most differential molecular features between CF and non-CF were molecules highly abundant in CF sputa, likely of host origin, as they did not match a microbial culture metabolome. However, it is important to note that different conditions of microbial culture may result in variable metabolite production.

Of the 30 molecular features identified in the VIP, many yielded an MS/MS fragmentation peak of

Figure 4 Molecular network highlighting xenobiotic metabolites detected through GNPS library searching in CF samples (green nodes). Successfully annotated xenobiotic molecular families and associated chemical structures are highlighted including nodes representing particular transformations and breakdown products.

m/z 184.07 which corresponded to phosphocholine (Supplementary Figure S6). This fragmentation pattern indicated that these differential metabolites were phospholipids, particularly the sphingolipids, which are rare in bacteria and fungi (Olsen and Jantzen, 2001; Wieland Brown *et al.*, 2013). One particularly differential molecule (m/z 703.58), highly abundant in CF, was annotated as the lipid sphingomyelin (18:1/16:0) (Supplementary Figure S7). Three additional sphingomyelins were detected in the VIP (m/z 675.54, m/z 689.56 and m/z 701.56). The sphingomyelin molecular cluster in the CF/non-CF molecular network visualized these sphingomyelins and a number of other related molecules not identified in the VIP (Figure 5a). Manual annotation of the MS/MS spectra of these molecules, in conjunction with searches of the LipidMaps database (Sud *et al.*, 2006), putatively annotated them as related sphingomyelins. All putative sphingomyelins detected in the molecular cluster in Figure 5a were significantly elevated in CF vs non-CF sputa according to the Wilcoxon rank-sum test (two-tailed), including d18:1/16:0 (m/z 703.58, $P=0.002$), d18:1/14:0 (m/z 675.54, $P=0.002$), d18:1/15:0 (m/z 689.56, $P=0.01$) and d18:1/16:1 (m/z 701.56, $P=0.003$, $df=13$, Figure 5a). The glycosphingolipids, tetra-glycosceramide (d18:1/16:0, m/z 1227.76) and

lactosylceramide (d18:1/16:0, m/z 862.62) were also identified with the random forests VIP and significantly more abundant in CF sputa ($P=0.009$ and 0.02 , respectively, Supplementary Figure S6, Supplementary Table S4). To determine whether sphingolipid forms were especially abundant as opposed to other phospholipids, the area under the curves of the C18 lipids ceramide (18:1/16:0), sphingomyelin (18:1/16:0), and diacylglycerophosphocholine (18:1/16:0) were compared. Significant differences in abundance were only found for the C18 sphingolipids ceramide ($P=0.002$) and sphingomyelin ($P=0.004$), but not for the C18 diacylglycerophosphocholine ($P=0.1$, Figure 5b, Wilcoxon rank-sum test). The sphingolipids were not significantly correlated with any particular bacterial genus.

Discussion

This study investigated the global chemistry of CF sputum comparing findings to clinical culture history and microbial 16S rRNA gene profiles. We found that sputum is a diverse sample containing molecules from microbial, host and xenobiotic sources. What was unexpected, however, was that microbial molecules were not particularly abundant and the microbiome diversity was not correlated with metabolome diversity. The most abundant molecules in CF sputum were sphingolipids and antibiotics. Sphingolipids were significantly more abundant in CF sputum than in non-CF sputum, indicating that they may accumulate in the lungs of CF patients. This discrepancy between microbial and metabolite diversity is likely due to the high abundance and diversity of host metabolites coming from inflammatory cells in sputum (Macher and Klock, 1980; Dechechi *et al.*, 2011).

Clinical culturing, 16S rRNA gene profiling and metabolite-based detection were not congruent for the diagnosis of a *P. aeruginosa* infection (Tables 1 and 2). It was found that patients without a known *P. aeruginosa* infection contained the bacterium's molecules in their sputum and *vice versa*. For example, patient CF13 had abundant reads (67.9%) mapped to *P. aeruginosa* in the sputum microbiome, but was clinically classified as being infected by MRSA, and LC-MS/MS did not detect any *P. aeruginosa* specialized metabolites. Similarly, CF1 had abundant *P. aeruginosa* reads in the 16S rRNA microbiome profile and was classified as a *Stenotrophomonas maltophilia*/*P. aeruginosa* infection by culture, but *P. aeruginosa* metabolites were absent. Three patients had low amounts of *P. aeruginosa* in their microbiome, but LC-MS/MS detected the rhamnolipid Rha-Rha-C10-C10. Patient CF9, however, had signatures of *P. aeruginosa* using all three methods of detection. In light of these results, we further investigated the presence of *P. aeruginosa* molecules in another 27 sputum

Figure 5 (a) The molecular network cluster of sphingolipids and related molecules in sputum data. Node size was scaled according to their abundances using the Cytoscape software. Nodes identified in the random forests VIP are shown as squares, and round nodes were not identified by random forests. Annotation of sphingomyelin (d18:1/16:0) was verified with a purchased standard and its chemical structure is shown. Putative annotations of other nodes in the cluster are according to the LipidMaps database and guided by MS/MS fragmentation spectra. Abundances of the metabolites in the cluster are shown using boxplots from CF and non-CF area under the curve data with attention to the most abundant molecules. (b) Area under the curve abundances of ceramide (Cer), sphingomyelin (SM) and C18 phosphocholine (PC) in CF and non-CF sputa. Statistically significant differences were determined using a Wilcoxon rank-sum test.

samples and found similar discrepancies with clinical culture. Of the samples tested, 21% were culture positive, but negative for *P. aeruginosa* metabolites. Thus, clinical culture and microbiome results do not reflect the active production of *P. aeruginosa* small molecules. Rhamnolipids, for example, may be produced by *P. aeruginosa* active metabolism despite its overall low abundance or ability to be cultured on selective media. Identification of actively growing bacteria is of particular interest for antibiotic treatment, as antibiotics are most effective against actively growing cells (Hu and Coates, 2012). Clinical decisions should take into account the potential that culture identifications are not necessarily reflective of active growth and metabolite production of a particular bacterium.

The molecules produced by *P. aeruginosa* grown in culture did not match those produced in CF sputum, demonstrating that the bacterium's specialized metabolite production is unique in the lung environment. For example, in patient CF9, quinolones were detected, but PQS, the best-studied *P. aeruginosa* quinolone, was completely absent even though it was readily detected from cultured cells under the same LC-MS/MS conditions. The most abundant quinolone detected was HHQ, the biosynthetic precursor of PQS. This phenomenon was verified in another 27 sputum samples by targeted quinolone analysis. We hypothesize that the absence of PQS in the sputa is due to the high concentration of iron (Stites *et al.*, 1998; Ghio *et al.*, 2012) and low concentration of oxygen (Schertzer

et al., 2010), which has been shown to inhibit PQS production (Bredenbruch *et al.*, 2006; Schertzer *et al.*, 2010). Growing *P. aeruginosa* in an environment mimicking the CF lung reproduced the specific quinolone production, indicating that the chemical conditions of a mucus-plugged bronchiole are likely responsible for the specific quinolone chemistry detected in sputum. The presence of HHQ and HQNO suggests that the historical research focus on PQS may not be relevant in the lung environment (Collier *et al.*, 2002; Bredenbruch *et al.*, 2006; Häussler and Becker, 2008), these other quinolones may be more important to the bacterium *in vivo*. A similar phenomenon has been observed with *P. aeruginosa* homoserine lactone quorum-sensing molecules, which also implicated the environment of the CF lung as the driver of the unexpected chemistry (Singh *et al.*, 2000). Close molecular relatives of phenazines were detected in CF6, indicating that those that are produced in the lung may include previously unrecognized molecules. Rhamnolipid production also varied, where 12 specific rhamnolipids were produced by cultured *P. aeruginosa* cells, but only 1 detected in sputum. The disparity between the specific chemistry of *P. aeruginosa* small molecules in culture and *in vivo* is likely due to differential abundance of the bacterium, clonal adaptation and hyper-mutation affecting its phenotype, and the effects of the complex lung environment on the bacterium's physiology (Wilder *et al.*, 2009; Hogardt and Heesemann, 2010; Behrends *et al.*, 2013; Workentine *et al.*, 2013). This study

demonstrates the importance of growing the bacterium in an environment better mimicking the CF lung, an approach that has previously revealed important aspects of *P. aeruginosa* physiology as a CF pathogen (Palmer et al., 2005, 2007; Sriramulu et al., 2005; Fung et al., 2010; Hare et al., 2012; Quinn et al., 2014; Turner et al., 2015).

The most differential metabolites between CF and non-CF sputa were sphingolipids. Sphingolipids are rare in bacteria and fungi and therefore likely host derived. However, some microbes have been documented to produce them, including a bacterium detected in our microbiome profiles (*Prevotella*) (Olsen and Jantzen, 2001; Wieland Brown et al., 2013). Molecular networking revealed that there was a diverse complement of sphingolipids highly abundant in CF lungs including various sphingomyelins, lactosylceramide, tetraglycoceramide, ceramides and sphingosine. Hydrolysis of the hydrophilic head group of sphingolipids produces ceramide, which induces strong inflammatory cascades (Brodlie et al., 2011). Thus, the abundance of sphingomyelins found in this study represents a large reservoir of ceramide induced inflammatory signaling that could be harmful to the lungs. In support of these findings, elevated levels of ceramide have been measured in the epithelial membrane of CF mice and late-stage CF patients (Teichgräber et al., 2008; Brodlie et al., 2011; Ziobro et al., 2013). Recent studies suggest that CFTR is directly involved in the regulation of ceramide metabolism, because CFTR knockouts accumulate ceramide in the epithelium (Bodas et al., 2011; Ziobro et al., 2013). Our findings support previous studies that have focused on the human enzyme acid sphingomyelinase, which converts sphingomyelin to ceramide and is activated by microbial products and inflammatory cytokines (Sakata et al., 2007). *P. aeruginosa* also produces a phospholipase that can act as a sphingomyelinase (Truan et al., 2013). These enzymes have been suggested as a target for novel therapies to reduce lung inflammation (Teichgräber et al., 2008; Ziobro et al., 2013), because their mechanistic action can contribute to the harmful hyperinflammation characteristic of CF disease. In addition, sphingolipids have been shown to have a CFTR-dependent role in vasoconstriction through hypoxia signaling (Tabeling et al., 2015), a potentially important link between sphingolipids and the host response to the hypoxic CF lung that drives microbial physiology (Quinn et al., 2014). Sphingolipid accumulation is not specific to CF disease, it has also been observed in other inflammatory lung diseases, such as asthma (Ammit et al., 2001), emphysema (Petrache et al., 2005) and chronic obstructive pulmonary disorder (Telenga et al., 2014). Regardless of its disease specificity or source of production, the exceptionally high abundance of these molecules in CF sputum further supports that targeting sphingomyelinases can be a potentially efficacious treatment for CF.

The molecular networking approach in this study revealed that CF sputum is a heterogeneous *milieu* of host, microbial and xenobiotic chemical products. Xenobiotics were in high relative abundance in sputa. Common drugs used to treat CF patients were identified including antibiotics, antifungals and antidepressants. We also observed metabolism of these drugs, including desulfation, methylation, hydroxylation, acetylation and removal of sugars. The ability of molecular networking to visualize the chemistry and metabolism of drugs in the same sample along with microbial products can inform physicians about which microbes are active in a particular sample and their antibiotic resistance mechanisms. This is important knowledge and can influence subsequent treatment regimes. Furthermore, this analysis can be done on a patient-by-patient basis to allow for precision care. Metabolomics studies are often limited by the need to analyze a particular targeted group of compounds. Application of molecular networking to metabolomics greatly increases the comprehensiveness and ability to study the effects of small molecules on host and microbial physiology together with one method.

Conclusions

This study described the chemical makeup of CF sputum and found that the most abundant molecules were sphingolipids. Drugs targeting the conversion of sphingolipids to ceramide, such as amitriptyline, already prescribed for some CF patients (Riethmüller et al., 2009) and detected in this study, may be efficacious in reducing the overall hyperinflammation across individuals. There was a marked discrepancy in 16S rRNA gene sequencing, clinical culture and metabolomics results for the detection of *P. aeruginosa* in a sputum sample. Clinical decisions for antibiotic use are currently based on results from routine microbiological culture on selective media. This study indicates that treatment decisions based on culture results need to consider that culture-based detection of a bacterium does not imply that it is actively growing and producing potentially damaging metabolites in the patient. Metabolomics methods can detect microbial metabolites unique to particular bacteria or groups of bacteria and could aid clinical decisions by providing evidence that a particular pathogen is active in a clinical sample.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

We thank the following for financial support: National Institute of Health (NIH) Grants R01GM095384 (FLR) and its administrative supplement 3R01GM095384-03S1

subcontracted to FLR and PCD, GM103809 (VVP), S10RR029121 (to PCD), the National Science Foundation grant CNS-1305112 to Robert A. Edwards (SDSU) and the University of California San Diego Clinical and Translational Research project #UL1 RR031980 (to DJC). We also would like to acknowledge the Bruker Therapeutic Discovery Mass Spectrometry Center at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences. We would like to thank Savannah Sanchez, Nate Robinett and Natasha Talago for their contributions. We would like to also thank the Cystic Fibrosis Research Inc. (CFRI) who sponsored RAQ with the Elizabeth Nash Memorial Fellowship. The authors and their colleagues in the Rohwer laboratory would like to dedicate this manuscript to Mr Mike Furlan, whose enthusiasm for life and science will live long in our memories.

References

- Allen L, Dockrell DH, Pattery T, Lee DG, Cornelis P, Hellewell PG *et al.* (2005). Pyocyanin production by *Pseudomonas aeruginosa* induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. *J Immunol* **174**: 3643–3649.
- Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP *et al.* (2001). Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. *FASEB J* **15**: 1212–1214.
- Bandeira N, Tsur D, Frank A, Pevzner PA. (2007). Protein identification by spectral networks analysis. *Proc Natl Acad Sci USA* **104**: 6140–6145.
- Barker M, Hengst M, Schmid J, Buers H-J, Mittermaier B, Klemp D *et al.* (2006). Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis. *Eur Respir J* **27**: 929–936.
- Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, Williams HD. (2013). Metabolic adaptations of *Pseudomonas aeruginosa* during cystic fibrosis chronic lung infections. *Environ Microbiol* **15**: 398–408.
- Bensel T, Stotz M, Borneff-Lipp M, Wollschläger B, Wienke A, Taccetti G *et al.* (2011). Lactate in cystic fibrosis sputum. *J Cyst Fibros* **10**: 37–44.
- Blainey PC, Milla CE, Cornfield DN, Quake SR. (2012). Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. *Sci Transl Med* **4**: 153ra130.
- Bodas M, Min T, Mazur S, Vij N. (2011). Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. *J Immunol* **186**: 602–613.
- Bredenbruch F, Geffers R, Nimtz M, Buer J, Häussler S. (2006). The *Pseudomonas aeruginosa* quinolone signal (PQS) has an iron-chelating activity. *Environ Microbiol* **8**: 1318–1329.
- Brodie M, Lordan JL, Ward C. (2011). Ceramide and cystic fibrosis lung disease. *Am J Respir Crit Care Med* **183**: 133.
- Calfee MW, Coleman JP, Pesci EC. (2001). Interference with *Pseudomonas* quinolone signal synthesis inhibits virulence factor expression by *Pseudomonas aeruginosa*. *Proc Natl Acad Sci USA* **98**: 11633–11637.
- Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ *et al.* (2011). Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc Natl Acad Sci USA* **108**: 4516–4522.
- Celio S, Troxler H, Durka SS, Chládek J, Wildhaber JH, Sennhauser FH *et al.* (2006). Free 3-nitrotyrosine in exhaled breath condensates of children fails as a marker for oxidative stress in stable cystic fibrosis and asthma. *Nitric Oxide* **15**: 226–232.
- Cole JR, Chai B, Farris RJ, Wang Q, Kulam SA, McGarrell DM *et al.* (2005). The Ribosomal Database Project (RDP-II): sequences and tools for high-throughput rRNA analysis. *Nucleic Acids Res* **33**: D294–D296.
- Collier DN, Anderson L, McKnight SL, Noah TL, Knowles M, Boucher R *et al.* (2002). A bacterial cell to cell signal in the lungs of cystic fibrosis patients. *FEMS Microbiol Lett* **215**: 41–46.
- Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hafiz T, Hoffman LR *et al.* (2014). Time between collection and storage significantly influences bacterial sequence composition in sputum samples from cystic fibrosis respiratory infections. *J Clin Microbiol* **52**: 3011–3016.
- Dechecchi MC, Nicolis E, Mazzi P, Cioffi F, Bezzerri V, Lampronti I *et al.* (2011). Modulators of sphingolipid metabolism reduce lung inflammation. *Am J Respir Cell Mol Biol* **45**: 825–833.
- Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S *et al.* (2012). The airway microbiota in cystic fibrosis: a complex fungal and bacterial community—implications for therapeutic management. *PLoS One* **7**: e36313.
- Dettmer K, Aronov PA, Hammock BD. (2007). Mass spectrometry-based metabolomics. *Mass Spectrom Rev* **26**: 51–78.
- Diggle SP, Matthijs S, Wright VJ, Fletcher MP, Chhabra SR, Lamont IL *et al.* (2007). The *Pseudomonas aeruginosa* 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. *Chem Biol* **14**: 87–96.
- Eiserich JP, Yang J, Morrissey BM, Hammock BD, Cross CE. (2012). Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions. *Ann NY Acad Sci* **1259**: 1–9.
- Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML *et al.* (2012). Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. *J Bacteriol* **194**: 4709–4717.
- Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J *et al.* (2010). Gene expression of *Pseudomonas aeruginosa* in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. *J Med Microbiol* **59**: 1089–1100.
- Ghio AJ, Roggli VL, Soukup JM, Richards JH, Randell SH, Muhlebach MS. (2012). Iron accumulates in the lavage and explanted lungs of cystic fibrosis patients. *J Cyst Fibros* **12**: 390–398.
- Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML *et al.* (2012). Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. *Proc Natl Acad Sci USA* **109**: 13769–13774.
- Guss AM, Roeselers G, Newton ILG, Young CR, Klepac-Ceraj V, Lory S *et al.* (2011). Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. *ISME J* **5**: 20–29.
- Hare NJ, Soe CZ, Rose B, Harbour C, Codd R, Manos J *et al.* (2012). Proteomics of *Pseudomonas aeruginosa*

- Australian epidemic strain 1 (AES-1) cultured under conditions mimicking the cystic fibrosis lung reveals increased iron acquisition via the siderophore pyochelin. *J Proteome Res* **11**: 776–795.
- Harrison F. (2007). Microbial ecology of the cystic fibrosis lung. *Microbiology* **153**: 917–923.
- Häussler S, Becker T. (2008). The pseudomonas quinolone signal (PQS) balances life and death in *Pseudomonas aeruginosa* populations. *PLoS Pathog* **4**: e1000166.
- Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Cámara M. (2011). Quinolones: from antibiotics to autoinducers. *FEMS Microbiol Rev* **35**: 247–274.
- Hogardt M, Heesemann J. (2010). Adaptation of *Pseudomonas aeruginosa* during persistence in the cystic fibrosis lung. *Int J Med Microbiol* **300**: 557–562.
- Hu Y, Coates A. (2012). Nonmultiplying bacteria are profoundly tolerant to antibiotics. *Handb Exp Pharmacol* **211**: 99–119.
- Hunter RC, Klepac-Ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. (2012). Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. *Am J Respir Cell Mol Biol* **47**: 738–745.
- Irie Y, O'toole GA, Yuk MH. (2005). *Pseudomonas aeruginosa* rhamnolipids disperse Bordetella bronchiseptica biofilms. *FEMS Microbiol Lett* **250**: 237–243.
- Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, Grisham MB *et al.* (2000). Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum. *Pediatr Pulmonol* **30**: 79–85.
- Knowles MR, Stutts MJ, Spock A, Fischer N, Gatzky JT, Boucher RC. (1983). Abnormal ion permeation through cystic fibrosis respiratory epithelium. *Science* **221**: 1067–1070.
- Kownatzki R, Tümmler B, Döring G. (1987). Rhamnolipid of *Pseudomonas aeruginosa* in sputum of cystic fibrosis patients. *Lancet* **1**: 1026–1027.
- Lim YW, Evangelista JS, Schmieder R, Bailey B, Haynes M, Furlan M *et al.* (2014). Clinical insights from metagenomic analysis of cystic fibrosis sputum. *J Clin Microbiol* **52**: 425–457.
- Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M *et al.* (2013). Metagenomics and metatranscriptomics: Windows on CF-associated viral and microbial communities. *J Cyst Fibros* **12**: 154–164.
- Macher B, Klock J. (1980). Isolation and chemical characterization of neutral glycosphingolipids of human neutrophils. *J Biol Chem* **255**: 2092–2096.
- Maughan H, Wang PW, Diaz Caballero J, Fung P, Gong Y, Donaldson SL *et al.* (2012). Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions. *PLoS One* **7**: e45791.
- Mitchell G, Séguin DL, Asselin A-E, Déziel E, Cantin AM, Frost EH *et al.* (2010). Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to *Pseudomonas aeruginosa* 4-hydroxy-2-heptylquinoline-N-oxide. *BMC Microbiol* **10**: 33.
- Molloy S. (2014). Bacterial physiology: a metabolic milieu. *Nat Rev Microbiol* **12**: 315.
- Monge ME, Pérez JJ, Dwivedi P, Zhou M, McCarty NA, Stecenko AA *et al.* (2013). Ion mobility and liquid chromatography/mass spectrometry strategies for exhaled breath condensate glucose quantitation in cystic fibrosis studies. *Rapid Commun Mass Spectrom* **27**: 2263–2271.
- Montuschi P, Paris D, Melck D, Lucidi V, Ciabattini G, Raia V *et al.* (2012). NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. *Thorax* **67**: 222–228.
- Moree WJ, Phelan VV, Wu C-H, Bandeira N, Cornett DS, Duggan BM *et al.* (2012). Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. *PNAS* **109**: 13811–13816.
- Newport S, Amin N, Dozor AJ. (2009). Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations. *Pediatr Pulmonol* **872**: 866–872.
- Nguyen DD, Wu C-H, Moree WJ, Lamsa A, Medema MH, Zhao X *et al.* (2013). MS/MS networking guided analysis of molecule and gene cluster families. *Proc Natl Acad Sci USA* **110**: E2611–E2620.
- Oksanen, Blanchet FG, Kindt R, Legendre P, Minchin PR, RO'Hara R *et al.* (2015). Vegan: Community ecology. CRAN R Packag version 23-0. Available from <http://CRAN.R-project.org/package=vegan>.
- Olsen I, Jantzen E. (2001). Sphingolipids in bacteria and fungi. *Anaerobe* **7**: 103–112.
- Palmer KL, Aye LM, Whiteley M. (2007). Nutritional cues control *Pseudomonas aeruginosa* multicellular behavior in cystic fibrosis sputum. *J Bacteriol* **189**: 8079–8087.
- Palmer KL, Mashburn LM, Singh PK, Whiteley M. (2005). Cystic fibrosis sputum supports growth and cues key aspects of *Pseudomonas aeruginosa* physiology. *J Bacteriol* **187**: 5267–5277.
- Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C *et al.* (2005). Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. *Nat Med* **11**: 491–498.
- Pierson LS, Pierson EA. (2010). Metabolism and function of phenazines in bacteria: impacts on the behavior of bacteria in the environment and biotechnological processes. *Appl Microbiol Biotechnol* **86**: 1659–1670.
- Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG *et al.* (2013). Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. *Microbiome* **1**: 27.
- Price-Whelan A, Dietrich LEP, Newman DK. (2006). Rethinking 'secondary' metabolism: physiological roles for phenazine antibiotics. *Nat Chem Biol* **2**: 71–78.
- Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P *et al.* (2013). The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* **41**: D590–D596.
- Quinn RA, Lim YW, Maughan H, Conrad D, Rohwer F, Whiteson KL. (2014). Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. *MBio* **5**: e00956–13.
- Quinn RA, Whiteson K, Lim Y, Salamon P, Bailey B, Mienardi S *et al.* (2014). A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. *ISME J* **9**: 1024–1038.
- Quinton PM. (1983). Chloride impermeability in cystic fibrosis. *Nature* **301**: 421–422.
- Quinton PM. (2008). Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. *Lancet* **372**: 415–417.
- Rada B, Lekstrom K, Damian S, Dupuy C, Leto TL. (2008). The *Pseudomonas* toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. *J Immunol* **181**: 4883–4893.

- Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E. (2009). Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. *Cell Physiol Biochem* **24**: 65–72.
- Robroeks CM, van Berkel J, Dallinga JW, Jöbsis Q, Zimmermann L, Hendriks HJ *et al.* (2010). Metabolomics of volatile organic compounds in cystic fibrosis patients and controls. *Pediatr Res* **68**: 75–80.
- Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. (2003). Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. *J Clin Microbiol* **41**: 3548–3558.
- Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S *et al.* (2007). Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. *Immunology* **122**: 54–64.
- Salipante SJ, Sengupta DJ, Rosenthal C, Costa G, Spangler J, Sims EH *et al.* (2013). Rapid 16S rRNA next-generation sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections. *PLoS One* **8**: e65226.
- Schertzer JW, Brown SA, Whiteley M. (2010). Oxygen levels rapidly modulate *Pseudomonas aeruginosa* social behaviours via substrate limitation of PqsH. *Mol Microbiol* **77**: 1527–1538.
- Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB *et al.* (2009). Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol* **75**: 7537–7541.
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D *et al.* (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* **13**: 2498–2504.
- Sidebottom AM, Johnson AR, Karty JA, Trader DJ, Carlson EE. (2013). Integrated metabolomics approach facilitates discovery of an unpredicted natural product suite from *Streptomyces coelicolor* M145. *ACS Chem Biol* **8**: 2009–2016.
- Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. (2000). Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature* **407**: 762–764.
- Smith DJ, Badrick AC, Zakrzewski M, Krause L, Bell SC, Anderson GJ *et al.* (2014). Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. *Eur Respir J* **44**: 922–930.
- Sriramulu DD, Lünsdorf H, Lam JS, Römling U. (2005). Microcolony formation: a novel biofilm model of *Pseudomonas aeruginosa* for the cystic fibrosis lung. *J Med Microbiol* **54**: 667–676.
- Stites SW, Walters B, O'Brien-Ladner A, Bailey K, Wesseliuss L. (1998). Increased iron and ferritin content of sputum from patients with cystic fibrosis or chronic bronchitis. *Chest* **114**: 814.
- Sud M, Fahy E, Cotter D, Brown A, Dennis E, Glass C *et al.* (2006). LMSD: lipid MAPS structure database. *Nucleic Acids Res* **35**: D527–D532.
- Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA *et al.* (2007). Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics* **3**: 211–221.
- Tabeling C, Yu H, Wang L, Ranke H, Goldenberg NM, Zabini D *et al.* (2015). CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction. *Proc Natl Acad Sci USA* **112**: E1614–E1623.
- Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC *et al.* (2008). Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. *Nat Med* **14**: 382–391.
- Telenga ED, Hoffmann RF, Ruben t'Kindt, Hoonhorst SJM, Willemse BWM, van Oosterhout AJM *et al.* (2014). Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. *Am J Respir Crit Care Med* **190**: 155–164.
- Truan D, Vasil A, Stonehouse M, Vasil ML, Pohl E. (2013). High-level over-expression, purification, and crystallization of a novel phospholipase C/sphingomyelinase from *Pseudomonas aeruginosa*. *Protein Expr Purif* **90**: 40–46.
- Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. (2015). Essential genome of *Pseudomonas aeruginosa* in cystic fibrosis sputum. *Proc Natl Acad Sci USA* **112**: 4110–4115.
- Twomey KB, Alston M, An S-Q, O'Connell OJ, McCarthy Y, Swarbreck D *et al.* (2013). Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. *PLoS One* **8**: e82432.
- Watrous J, Roach P, Alexandrov T, Heath BS, Yang JY, Kersten RD *et al.* (2012). Mass spectral molecular networking of living microbial colonies. *Proc Natl Acad Sci USA* **109**: 1743–1752.
- Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H, Quinn R *et al.* (2014). Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. *ISME J* **8**: 1247–1258.
- Widdicombe JH, Welsh MJ, Finkbeiner WE. (1985). Cystic fibrosis decreases the apical membrane chloride permeability of monolayers cultured from cells of tracheal epithelium. *PNAS* **82**: 6167–6171.
- Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M *et al.* (2013). Production of α -galactosylceramide by a prominent member of the human gut microbiota. *PLoS Biol* **11**: e1001610.
- Wilder CN, Allada G, Schuster M. (2009). Instantaneous within-patient diversity of *Pseudomonas aeruginosa* quorum-sensing populations from cystic fibrosis lung infections. *Infect Immun* **77**: 5631–5639.
- Willger SD, Grim SL, Dolben EL, Shipunova A, Hampton TH, Morrison HG *et al.* (2014). Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis. *Microbiome* **2**: 40.
- Willner D, Furlan M, Haynes M, Schmieder R, Angly FE, Silva J *et al.* (2009). Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. *PLoS One* **4**: e7370.
- Willner D, Haynes MR, Furlan M, Schmieder R, Lim YW, Rainey PB *et al.* (2012). Spatial distribution of microbial communities in the cystic fibrosis lung. *ISME J* **6**: 471–474.
- Wolak JE, Esther CR, O'Connell TM. (2009). Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. *Biomarkers* **14**: 55–60.

- Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD *et al.* (2013). Phenotypic heterogeneity of *Pseudomonas aeruginosa* populations in a cystic fibrosis patient. *PLoS One* **8**: e60225.
- Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD. (2012). Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. *Free Radic Biol Med* **53**: 160–171.
- Yang JY, Sanchez LM, Rath CM, Liu X, Boudreau PD, Bruns N *et al.* (2013). Molecular networking as a dereplication strategy. *J Nat Prod* **76**: 1686–1699.
- Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ *et al.* (2013). Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. *PLoS One* **8**: e62917.
- Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF *et al.* (2012). Decade-long bacterial community dynamics in cystic fibrosis airways. *Proc Natl Acad Sci USA* **109**: 5809–5814.
- Ziobro R, Henry B, Edwards MJ, Lentsch AB, Gulbins E. (2013). Ceramide mediates lung fibrosis in cystic fibrosis. *Biochem Biophys Res Commun* **434**: 705–709.
- Zulianello L, Canard C, Köhler T, Caille D, Lacroix J-S, Meda P. (2006). Rhamnolipids are virulence factors that promote early infiltration of primary human airway epithelia by *Pseudomonas aeruginosa*. *Infect Immun* **74**: 3134–3147.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

Supplementary Information accompanies this paper on The ISME Journal website (<http://www.nature.com/ismej>)